首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1387146

多克隆抗体市场报告：2030 年趋势、预测和竞争分析

Polyclonal Antibodie Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2023年10月27日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

多克隆抗体的趋势与预测

预计到 2030 年，全球多株抗体市场将达到 68 亿美元，2024 年至 2030 年年复合成长率为 7.8%。该市场的主要驱动因素包括癌症和感染疾病患者的增加、生物製药业务研发力度的增加以及抗体药物技术开发的进步。全球多株抗体市场的未来前景广阔，学术研究中心、製药和生物技术公司、诊断中心和医院市场存在商机。

多克隆抗体市场洞察

Lucintel 预测诊断学将在预测期内实现最高增长，因为多克隆抗体生产成本低廉且可在许多物种中获得。

随着越来越多的公司将多克隆抗体用于各种目的，包括药物、诊断分析和研究工具，预计製药和生物技术公司仍将是该市场中最大的部分。

由于生物技术和製药行业的研发资金增加，以及该地区完善的医院、诊所和实验室医疗保健系统，北美在预测期内仍然是最大的地区，并且仍将是区域性的。

本报告回答了 11 个关键问题：

Q.1. 细分市场中最有前途和高成长的机会是什么？
Q.2.哪个细分市场将以更快的速度成长？为什么？
Q.3.您认为哪些地区未来会出现更快的成长？为什么？
Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
Q.5. 这个市场的商业风险和竞争威胁是什么？
Q.6.这个市场有哪些新趋势？为什么？
Q.7.市场客户需求有何改变？
Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

宏观经济趋势（2018-2023）与预测（2024-2030）
全球多株抗体市场趋势（2018-2023）与预测（2024-2030）
全球多克隆抗体市场（按产品）
- 一次
- 中学
按来源分類的全球多克隆抗体市场
- 兔子
- 山羊
- 羊
- 其他的
全球多克隆抗体市场（按应用）
- 研究
- 诊断
- 治疗
按最终用途分類的全球多克隆抗体市场
- 学术研究中心
- 製药和生物技术公司
- 诊断中心
- 医院

第4章2018-2030年分地区市场趋势及预测分析

全球多株抗体市场区域分布
北美多株抗体市场
欧洲多株抗体市场
亚太多克隆抗体市场
其他地区多株抗体市场

第5章竞争分析

产品系列分析
营运整合
波特五力分析

第6章成长机会与策略分析

成长机会分析
- 全球多克隆抗体市场成长机会（按产品）
- 全球多克隆抗体市场成长机会（按来源）
- 全球多克隆抗体市场成长机会（按应用）
- 全球多克隆抗体市场成长机会（依最终用途）
- 全球多克隆抗体市场成长机会（按地区）
全球多克隆抗体市场的新趋势
战略分析
- 新产品开发
- 全球多株抗体市场产能扩张
- 全球多克隆抗体市场的合併、收购和合资企业
- 认证和许可

第7章主要企业概况

Thermo Fisher Scientific
Merck Abcam
Bio-Rad Laboratories
F. Hoffmann-La Roche
Cell Signaling Technology
Becton and Dickinson
PerkinElmer
GenScript
ioLegend
Creative Diagnostics

简介目录

Polyclonal Antibodie Trends and Forecast

The future of the global polyclonal antibodie market looks promising with opportunities in the academic & research center, pharmaceutical & biotechnology company, diagnostic center, and hospital markets. The global polyclonal antibodie market is expected to reach an estimated $6.8 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are rising cancer cases and infectious diseases, increasing R&D efforts in the biopharmaceutical business, and as well as the increasing technological developments in antibody-based medications.

A more than 150-page report is developed to help in your business decisions.

Polyclonal Antibodie by Segment

The study includes a forecast for the global polyclonal antibodie by product, source, application, end use, and region.

Polyclonal Antibodie Market by Product [Shipment Analysis by Value from 2018 to 2030]:

Primary
Secondary

Polyclonal Antibodie Market by Source [Shipment Analysis by Value from 2018 to 2030]:

Rabbits
Goats
Sheep
Others

Polyclonal Antibodie Market by Application [Shipment Analysis by Value from 2018 to 2030]:

Research
Diagnostics
Therapy

Polyclonal Antibodie Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

Academic & Research Center
Pharmaceutical & Biotechnology Companies
Diagnostic Centers
Hospitals

Polyclonal Antibodie Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Polyclonal Antibodie Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies polyclonal antibodie companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the polyclonal antibodie companies profiled in this report include-

Thermo Fisher Scientific
Merck Abcam
Bio-Rad Laboratories
F. Hoffmann-La Roche
Cell Signaling Technology
Becton And Dickinson
Perkinelmer
Genscript
Iolegend
Creative Diagnostics

Polyclonal Antibodie Market Insights

Lucintel forecasts that diagnostics is expected to witness highest growth over the forecast period as polyclonal antibody manufacturing is inexpensive to produce and the presence of numerous species in it.

Within this market, pharmaceutical and biotechnology companies is expected to remain the largest segment due to he increasing use ofpolyclonal antibodies by the pharmaceutical and biotechnology industries for a range of purposes, including medicines, diagnostic assays, and research tools.

North America will remain the largest region during the forecast period due to the growing funding for research and development in the biotechnology and pharamceutical industries and well-established healthcare system that comprises hospitals, clinics, and laboratories in the region.

Features of the Global Polyclonal Antibodie Market

Market Size Estimates: Polyclonal antibodie market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Polyclonal antibodie market size by various segments, such as by product, source, application, end use, and region in terms of value ($B).

Regional Analysis: Polyclonal antibodie market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products sources, applications, end uses, and regions for the polyclonal antibodie market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the polyclonal antibodie market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the polyclonal antibodie market size?

Answer: The global polyclonal antibodie market is expected to reach an estimated $6.8 billion by 2030.

Q2. What is the growth forecast for polyclonal antibodie market?

Answer: The global polyclonal antibodie market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the polyclonal antibodie market?

Answer: The major drivers for this market are rising cancer cases and infectious diseases, increasing R&D efforts in the biopharmaceutical business, and as well as the increasing technological developments in antibody-based medications.

Q4. What are the major segments for polyclonal antibodie market?

Answer: The future of the polyclonal antibodie market looks promising with opportunities in the academic & research center, pharmaceutical & biotechnology company, diagnostic center, and hospital markets.

Q5. Who are the key polyclonal antibodie market companies?

Answer: Some of the key polyclonal antibodie companies are as follows:

Thermo Fisher Scientific
Merck Abcam
Bio-Rad Laboratories
F. Hoffmann-La Roche
Cell Signaling Technology
Becton And Dickinson
Perkinelmer
Genscript
Iolegend
Creative Diagnostics

Q6. Which polyclonal antibodie market segment will be the largest in future?

Answer: Lucintel forecasts that diagnostics is expected to witness highest growth over the forecast period as polyclonal antibody manufacturing is inexpensive to produce and the presence of numerous species in it.

Q7. In polyclonal antibodie market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region during the forecast period due to the growing funding for research and development in the biotechnology and pharamceutical industries and well-established healthcare system that comprises hospitals, clinics, and laboratories in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the polyclonal antibodie market by product (primary and secondary), source (rabbits, goats, sheep, and others), application (research, diagnostics, and therapy), end use (academic & research center, pharmaceutical & biotechnology companies, diagnostic centers, and hospitals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Polyclonal Antibodie Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Polyclonal Antibodie Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Polyclonal Antibodie Market by Product
- 3.3.1: Primary
- 3.3.2: Secondary
3.4: Global Polyclonal Antibodie Market by Source
- 3.4.1: Rabbits
- 3.4.2: Goats
- 3.4.3: Sheep
- 3.4.4: Others
3.5: Global Polyclonal Antibodie Market by Application
- 3.5.1: Research
- 3.5.2: Diagnostics
- 3.5.3: Therapy
3.6: Global Polyclonal Antibodie Market by End Use
- 3.6.1: Academic & Research Center
- 3.6.2: Pharmaceutical & Biotechnology Companies
- 3.6.3: Diagnostic Centers
- 3.6.4: Hospitals

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Polyclonal Antibodie Market by Region
4.2: North American Polyclonal Antibodie Market
- 4.2.2: North American Polyclonal Antibodie Market by End Use: Academic & Research Center, Pharmaceutical & Biotechnology Companies, Diagnostic Centers, and Hospitals
4.3: European Polyclonal Antibodie Market
- 4.3.1: European Polyclonal Antibodie Market by Application: Research, Diagnostics, and Therapy
- 4.3.2: European Polyclonal Antibodie Market by End Use: Academic & Research Center, Pharmaceutical & Biotechnology Companies, Diagnostic Centers, and Hospitals
4.4: APAC Polyclonal Antibodie Market
- 4.4.1: APAC Polyclonal Antibodie Market by Application: Research, Diagnostics, and Therapy
- 4.4.2: APAC Polyclonal Antibodie Market by End Use: Academic & Research Center, Pharmaceutical & Biotechnology Companies, Diagnostic Centers, and Hospitals
4.5: ROW Polyclonal Antibodie Market
- 4.5.1: ROW Polyclonal Antibodie Market by Application: Research, Diagnostics, and Therapy
- 4.5.2: ROW Polyclonal Antibodie Market by End Use: Academic & Research Center, Pharmaceutical & Biotechnology Companies, Diagnostic Centers, and Hospitals

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Polyclonal Antibodie Market by Product
- 6.1.2: Growth Opportunities for the Global Polyclonal Antibodie Market by Source
- 6.1.3: Growth Opportunities for the Global Polyclonal Antibodie Market by Application
- 6.1.4: Growth Opportunities for the Global Polyclonal Antibodie Market by End Use
- 6.1.5: Growth Opportunities for the Global Polyclonal Antibodie Market by Region
6.2: Emerging Trends in the Global Polyclonal Antibodie Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Polyclonal Antibodie Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Polyclonal Antibodie Market
- 6.3.4: Certification and Licensing